Impax Laboratories (IPXL) Misses Q2 EPS by 1c

Impax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.34, $0.01 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $214.2 million versus the consensus estimate of $199.93 million.

For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Bernstein SocGen on Darden Restaurants (DRI): 'Story Intact'
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty